Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer

T cell-based immunotherapy has markedly expanded the therapeutic options in numerous cancers. However, these approaches still achieve only limited clinical benefit in triple negative breast cancer (TNBC) and bladder cancer. Although immune checkpoint inhibitors improve outcomes for a subset of patie...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Carlos Ávila-Nieto, Gundram Jung, Helmut R. Salih, Ilona Hagelstein
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-03-01
Serija:	Frontiers in Immunology
Teme:	immunotherapy triple negative breast cancer bladder cancer TROP-2 CD3 bispecific antibody
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1794705/full
Oznake:	Označite Brez oznak, prvi označite!